Press release from Companies
Publicerat: 2025-09-19 08:45:00
SensoDetect AB (publ) announces a major step in its international expansion and clinical leadership. Dr. Mohamed Hussein Atwa Ahmed, who successfully initiated the companys autism spectrum disorder (ASD) clinical program in Saudi Arabia, is now permanently based in Sweden, where he will align more closely with SensoDetect’s headquarters and R&D hub in the greater copenhagen region.
Dr. Atwa was first appointed Head of Research for the MENA region (June 7, 2024) and subsequently promoted to Global Head of Clinical Research (September 5, 2024), reflecting his instrumental role in developing SensoDetect’s clinical pipeline. He has overseen the ASD clinical study at Princess Nourah bint Abdulrahman University Hospital/King Abdullah Bin Abdulaziz University Hospital (KAAUH) in Riyadh. The interim results in 2025 validated key aspects of the company’s diagnostic methodology and AI performance, positioning SensoDetect for the next stage of regulatory approvals and commercialization.
"Dr. Atwa’s relocation to Sweden is a strategic milestone. It brings our clinical leadership even closer to our innovation center and accelerates the pathway to clinical excellence and broader commercialization," said PA Hedin, CEO of SensoDetect. "His leadership has secured a strong clinical backbone and his permanent presence in Sweden will further enhance our ability to deliver value for patients, partners, and shareholders."
Dr. Atwa commented: "SensoDetect is at the forefront of transforming psychiatric care. By integrating clinical expertise, AI, and international partnerships, we are building a foundation for scalable, cost-effective solutions in mental health. I am proud to now be based in Sweden, working hand-in-hand with our R&D and corporate teams, while continuing to support our international clinical programs."
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
